Table 1. Dataset of NBAT1 Differential Expression.
| Dataset Title | Sample Count | Data Source | P-value | Compare (A vs B) | FoldChange (A over B) |
|---|---|---|---|---|---|
| Breast invasive carcinoma: Breast carcinoma estrogen receptor status | 754 | TCGA | 2.60E-08 | Negative vs Positive | 1.38 |
| Breast invasive carcinoma: Combination of Chemotherapy and Hormone therapy | 328 | TCGA | 3.62E-02 | Chemotherapy vs Hormone therapy,chemotherapy | 1.36 |
| Breast invasive carcinoma: Drug Arimidex or not | 325 | TCGA | 6.53E-02 | Arimidex vs No_Arimidex | 0.8 |
| Breast invasive carcinoma: Normal vs Tumor | 894 | TCGA | 9.03E-14 | Normal vs Tumor | 2.01 |
| Breast invasive carcinoma: Progesterone receptor status | 751 | TCGA | 5.70E-06 | Negative vs Positive | 1.27 |
| Uterine corpus endometrioid carcinoma: Histological type | 301 | TCGA | 4.72E-04 | Endometrioid endometrial adenocarcinoma vs Serous endometrial adenocarcinoma | 0.47 |
| Uterine corpus endometrioid carcinoma: Person neoplasm cancer status | 283 | TCGA | 2.72E-02 | Tumor free vs With tumor | 0.37 |